Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Cara TherapeuticsMannKindPhibro Animal HealthVeruZIOPHARM Oncology
SymbolNASDAQ:CARANASDAQ:MNKDNASDAQ:PAHCNASDAQ:VERUNASDAQ:ZIOP
Price Information
Current Price$28.51$4.18$24.43$9.42$3.33
52 Week RangeBuyBuyHoldBuyHold
MarketRank™
Overall Score1.61.41.81.41.3
Analysis Score2.53.50.83.53.2
Community Score3.12.22.22.92.4
Dividend Score0.00.02.50.00.0
Ownership Score1.70.81.70.00.8
Earnings & Valuation Score0.60.61.90.60.0
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyHold
Consensus Price Target$34.50$6.63$21.50$19.20$5.90
% Upside from Price Target21.01% upside58.49% upside-11.99% downside103.82% upside77.18% upside
Trade Information
Market Cap$1.42 billion$1.04 billion$988.27 million$677.41 million$716.63 million
Beta1.72.280.460.712.28
Average Volume877,5075,835,671140,5493,806,4192,750,134
Sales & Book Value
Annual Revenue$19.89 million$63.04 million$800.40 million$42.59 million$150,000.00
Price / Sales71.4916.521.2315.914,777.55
CashflowN/AN/A$2.20 per shareN/AN/A
Price / CashN/AN/A11.10N/AN/A
Book Value$4.66 per share($0.92) per share$4.65 per share$0.43 per share$0.52 per share
Price / Book6.12-4.545.2521.916.40
Profitability
Net Income$-106,370,000.00$-51,900,000.00$33.55 million$-18,970,000.00$-117,800,000.00
EPS($2.49)($0.27)$1.08($0.11)($0.34)
Trailing P/E RatioN/AN/A23.05N/AN/A
Forward P/E RatioN/AN/A21.62N/AN/A
P/E GrowthN/AN/A2.00N/AN/A
Net Margins-360.35%-71.92%5.37%-44.55%N/A
Return on Equity (ROE)-64.36%N/A23.70%-23.72%-48.49%
Return on Assets (ROA)-53.22%-46.80%5.99%-13.80%-43.53%
Dividend
Annual PayoutN/AN/A$0.48N/AN/A
Dividend YieldN/AN/A1.96%N/AN/A
Three-Year Dividend GrowthN/AN/A20.00%N/AN/A
Payout RatioN/AN/A44.44%N/AN/A
Years of Consecutive Dividend GrowthN/AN/A1 YearsN/AN/A
Debt
Debt-to-Equity RatioN/AN/A1.97%N/AN/A
Current Ratio8.00%0.63%2.88%1.83%10.12%
Quick Ratio8.00%0.58%1.61%1.38%10.12%
Ownership Information
Institutional Ownership Percentage67.01%29.60%50.32%23.32%48.00%
Insider Ownership Percentage5.70%1.09%50.05%26.10%2.30%
Miscellaneous
Employees802401,700339103
Shares Outstanding49.88 million249.07 million40.45 million71.91 million215.21 million
Next Earnings Date5/10/2021 (Estimated)5/5/2021 (Estimated)5/6/2021 (Confirmed)5/12/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Zacks: Analysts Expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Will Announce Earnings of -$0.11 Per ShareZacks: Analysts Expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Will Announce Earnings of -$0.11 Per Share
americanbankingnews.com - April 14 at 8:40 PM
Will current price volatility hamper ZIOPHARM Oncology, Inc. (ZIOP) future potential?Will current price volatility hamper ZIOPHARM Oncology, Inc. (ZIOP) future potential?
marketingsentinel.com - April 13 at 12:26 PM
Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 ...Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 ...
apnews.com - April 7 at 1:30 PM
Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual MeetingZiopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting
finance.yahoo.com - April 7 at 1:30 PM
ZIOP Apr 2021 4.500 callZIOP Apr 2021 4.500 call
uk.finance.yahoo.com - April 4 at 8:46 AM
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Given Average Recommendation of "Hold" by BrokeragesZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Given Average Recommendation of "Hold" by Brokerages
americanbankingnews.com - March 27 at 2:58 AM
Analysts Advise You To Maintain Your Position In ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)Analysts Advise You To Maintain Your Position In ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
stocksregister.com - March 26 at 1:39 PM
Why Ziopharm Oncology Stock Is Sinking TodayWhy Ziopharm Oncology Stock Is Sinking Today
finance.yahoo.com - March 20 at 3:17 AM
ZIOPHARM Oncology (NASDAQ:ZIOP) Earns Hold Rating from Jefferies Financial GroupZIOPHARM Oncology (NASDAQ:ZIOP) Earns Hold Rating from Jefferies Financial Group
marketbeat.com - March 18 at 8:16 AM
Ziopharm Oncology IncShs HoldZiopharm Oncology IncShs Hold
markets.businessinsider.com - March 14 at 8:57 AM
Why Ziopharm Oncology Stock Is Jumping TodayWhy Ziopharm Oncology Stock Is Jumping Today
finance.yahoo.com - February 26 at 1:44 PM
Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full ...Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full ...
apnews.com - February 26 at 8:25 AM
Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host ...Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host ...
apnews.com - February 17 at 5:26 AM
Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021
finance.yahoo.com - February 16 at 5:33 PM
Glioblastoma map points to new protein targets and immuno-oncology approachesGlioblastoma map points to new protein targets and immuno-oncology approaches
fiercebiotech.com - February 11 at 3:10 PM
Chronic Lymphocytic Leukemia Treatment Market Trends, Growth Outlook, Business Overview, Sales Insights and COVID-19 Impact Analysis By 2023Chronic Lymphocytic Leukemia Treatment Market Trends, Growth Outlook, Business Overview, Sales Insights and COVID-19 Impact Analysis By 2023
marketwatch.com - February 10 at 8:18 AM
Analyzing ZIOPHARM Oncologys Unusual Options ActivityAnalyzing ZIOPHARM Oncology's Unusual Options Activity
finance.yahoo.com - February 8 at 2:38 PM
Small Cell Lung Cancer Therapeutics Market - Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, and ZIOPHARM Oncology.Small Cell Lung Cancer Therapeutics Market - Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, and ZIOPHARM Oncology.
openpr.com - February 5 at 5:29 PM
Ziopharm Oncology Announces Election of Robert Postma to its Board of DirectorsZiopharm Oncology Announces Election of Robert Postma to its Board of Directors
markets.businessinsider.com - February 5 at 12:29 PM
Ziopharm to Participate in Upcoming January ConferencesZiopharm to Participate in Upcoming January Conferences
finance.yahoo.com - December 23 at 8:15 PM
Companies Like ZIOPHARM Oncology (NASDAQ:ZIOP) Are In A Position To Invest In GrowthCompanies Like ZIOPHARM Oncology (NASDAQ:ZIOP) Are In A Position To Invest In Growth
finance.yahoo.com - December 23 at 3:15 PM
Ziopharm Oncology Announces Clearance of Taiwans First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and LymphomasZiopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas
marketwatch.com - December 22 at 10:33 PM
Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the ...Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the ...
apnews.com - December 22 at 12:31 PM
Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and LymphomasZiopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas
finance.yahoo.com - December 21 at 8:06 PM
Are Options Traders Betting on a Big Move in Ziopharm (ZIOP) Stock?Are Options Traders Betting on a Big Move in Ziopharm (ZIOP) Stock?
finance.yahoo.com - December 17 at 10:15 AM
WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm OncologyWaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology
finance.yahoo.com - December 17 at 10:15 AM
DateCompanyBrokerageAction
4/15/2021Cara TherapeuticsNeedham & Company LLCReiterated Rating
9/8/2020Cara TherapeuticsCanaccord GenuityReiterated Rating
5/19/2020Cara TherapeuticsCantor FitzgeraldBoost Price Target
4/21/2020Cara TherapeuticsHC WainwrightBoost Price Target
7/30/2019Cara TherapeuticsPiper Jaffray CompaniesBoost Price Target
5/29/2019Cara TherapeuticsLaidlawBoost Price Target
2/6/2019Cara TherapeuticsJefferies Financial GroupInitiated Coverage
1/15/2019Cara TherapeuticsBank of AmericaInitiated Coverage
3/11/2021MannKindSVB LeerinkBoost Price Target
2/24/2021MannKindBTIG ResearchBoost Price Target
2/17/2021MannKindOppenheimerReiterated Rating
6/15/2018MannKindMaxim GroupReiterated Rating
8/6/2020Phibro Animal HealthMorgan StanleyDowngrade
5/8/2020Phibro Animal HealthCredit Suisse GroupLower Price Target
3/31/2020Phibro Animal HealthG.ResearchUpgrade
2/6/2020Phibro Animal HealthGabelliDowngrade
1/28/2020Phibro Animal HealthBarclaysUpgrade
5/23/2019Phibro Animal HealthGuggenheimInitiated Coverage
12/14/2020VeruBrookline Capital ManagementBoost Price Target
3/20/2019VeruCIBCInitiated Coverage
3/12/2021ZIOPHARM OncologyRaymond JamesSet Price Target
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.